Psyence Biomedical Ltd. (PBM)
| Market Cap | 11.71M +285.3% |
| Revenue (ttm) | n/a |
| Net Income | -6.94M |
| EPS | -12.56 |
| Shares Out | 3.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,411 |
| Open | 3.040 |
| Previous Close | 3.010 |
| Day's Range | 2.940 - 3.150 |
| 52-Week Range | 1.920 - 74.938 |
| Beta | 1.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About PBM
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
Financial Performance
Financial StatementsNews
Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform
MINNEAPOLIS--(BUSINESS WIRE)--Tredium Solutions, a provider of pharmacy benefit management (PBM) technologies, has been selected to support the administration of Scripius' commercial, Medicare, and Me...
Psyence Biomedical announces U.S. engagement initiative focused on ibogaine
Psyence BioMed announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government sta...
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived ps...
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network Dosing initiates clinical evaluation of NPX-5, a GMP-comp...
Psyence Biomedical provides update on position in global ibogaine market
Psyence Biomedical (PBM) provided an update on its strategic position in the global ibogaine market, as regulatory and clinical interest in the compound continues to expand. Recent signals from U.S.
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain Through its investment in and collaboration with PsyLabs, the C...
Why Is Psyence Biomedical Stock (PBM) Up Today?
Psyence Biomedical stock was up on Friday after the company expanded its clinical trial network in Australia.
Psyence Biomedical Ltd trading resumes
15:11 EDT Psyence Biomedical (PBM) Ltd trading resumes
Psyence Biomedical Ltd trading halted, volatility trading pause
15:06 EDT Psyence Biomedical (PBM) Ltd trading halted, volatility trading pause
Psyence acknowledges reports on U.S. action to advance Ibogaine research
Psyence Biomedical (PBM) acknowledged recent reports that the U.S. administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occu...
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethic...
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine the...
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
“The strongest companies are built on the right foundations long before their moment arrives,” says CEO Jody Aufrichtig “The strongest companies are built on the right foundations long before their mo...
Psyence Biomedical announces export of psilocybin to Australia
Psyence Biomedical (PBM) announced the export of fully GMP-compliant manufactured psilocybin product NPX-5 to Australia. The product was manufactured at the Psyence Labs GMP-controlled production faci...
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine the...
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine ther...
Psyence Biomedical announces results of annual, special meeting
Psyence Biomedical (PBM) announced the voting results from its Annual and Special Meeting of Shareholders, held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of…
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine ther...
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world's most advanced psychedelic pharmaceutical grade manufacturers, thereby secu...
Psyence Biomedical announces settlement of shareholder litigation
Psyence Biomedical (PBM) entered into a settlement agreement to resolve a direct shareholder claim made by KAOS Capital. The claim, originally made on January 14 and amplified on January 26,…
Psyence BioMed Announces Settlement of Shareholder Litigation
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that it has entered into a settlement agreement to resolve a direc...
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse...
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that it adjourned its annual and special meeting of shareholders (...
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced effectiv...
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine ther...